 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

For the last three days, A.I.dvisor has detected that IGMS's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

IGM Biosciences (IGMS, $7.24) Aroon Indicator entered a Downtrend on September 18, 2023.

IGM Biosciences (IGMS, $7.36) Aroon Indicator entered a Downtrend on September 15, 2023.

This indicator may be signaling IGMS's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

IGM Biosciences (IGMS, $7.36) entered Uptrend as Momentum indicator ascends above 0 level on Sep 15, 2023

IGM Biosciences (IGMS, $7.21) Aroon Indicator entered a Downtrend on September 14, 2023.

Medivir to present at the Pareto Securities Healthcare Conference Medivir to present at the Pareto Securities Healthcare Conference PR Newswire STOCKHOLM, Sweden, Sept. 14, 2023 STOCKHOLM, Sweden...

Medivir to present at the Pareto Securities Healthcare Conference

IGM Biosciences (IGMS, $7.19) Aroon Indicator entered a Downtrend on September 13, 2023.

This indicator may be signaling that IGMS's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

IGM Biosciences (IGMS, $7.19) entered Downtrend as Momentum indicator drops below 0 level on Sep 13, 2023

IGM Biosciences (IGMS, $7.67) entered Uptrend as Momentum indicator ascends above 0 level on Sep 11, 2023

IGM Biosciences (IGMS, $7.67) Aroon Indicator entered a Downtrend on September 11, 2023.

Medivir's Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study Medivir's Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2...

Medivir's Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm’s product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.

Watchers	1,212
52-Wk Low	$6.45
52-Wk High	$28.20

Market Cap	$383.95M
Volume (M)	287,574.00
52-Wk High	$28.20
52-Wk Low	$6.45

Current Price	$7.28
Prev Close	$7.46
Open	$7.48
Dividend Yield	0.00%
50-Day Moving Average	$8.32
Beta	1.82
Avg. Volume	209,419.91
PE Ratio	-1.38

52-Week High	$28.20
52-Week Low	$6.45
Market Capitalization	$383.95M
EPS	-$5.27
Price to Book	1.48
Revenue Per Employee	$6,484.50
Enterprise Value/EBITDA	-0.30

IGMS IGM Biosciences Inc

About

Feed

News

Sentiment

Earnings

Fundamentals